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ABSTRACT
Background and objective: Percutaneous lung biopsy
for diagnostic sampling of peripheral lung nodules has
been widely performed by interventional radiologists
under computed tomography (CT) guidance. New tech-
nology allows pulmonologists to perform percutaneous
lung biopsies using electromagnetic (EM) guided tech-
nology. With the adoption of this new technique, the
safety, feasibility and diagnostic yield need to be
explored. The goal of this study was to determine the
safety, feasibility and diagnostic yield of EM-guided per-
cutaneous lung biopsy performed by pulmonologists.
Methods: We conducted a retrospective, multicentre
study of 129 EM-guided percutaneous lung biopsies that
occurred between November 2013 and March 2017. The
study consisted of seven academic and three community
medical centres.
Results: The average age of participants was 65.6 years,
BMI was 26.3 and 50.4% were females. The majority of
lesions were in the right upper lobe (37.2%) and left
upper lobe (31.8%). The mean size of the lesions was
27.31 mm and the average distance from the pleura was
13.2 mm. Practitioners averaged two fine-needle aspi-
rates and five core biopsies per procedure. There were
23 (17.8%) pneumothoraces, of which 16 (12.4%)
received small-bore chest tube placement. The diagnos-
tic yield of percutaneous lung biopsy was 73.7%. When
EM-guided bronchoscopic sampling was also performed
during the same procedural encounter, the overall diag-
nostic yield increased to 81.1%.
Conclusion: In this large multicentred series, the use of
EM guidance for percutaneous lung biopsies was safe
and feasible, with acceptable diagnostic yield in the
hands of pulmonologists. A prospective multicentre trial
to validate these findings is currently underway
(NCT03338049).
Key words: lung cancer, bronchoscopy and interventional
techniques, pneumothorax, pathology.
INTRODUCTION
The National Lung Screening Trial (NLST) showed a
20% mortality decrease when using low-dose computed
Correspondence: Lonny Yarmus, Division of Pulmonary and
Critical Care Medicine, Johns Hopkins University School of
Medicine, 1830 East Monument Street, 5th Floor, Baltimore, MD
21287, USA. Email: lyarmus@jhmi.edu
Received 17 July 2018; invited to revise 24 August and
25 November 2018; revised 3 and 28 November 2018; accepted
10 December 2018 (Associate Editor: Pyng Lee; Senior Editor:
Phan Nguyen).
SUMMARY AT A GLANCE
Lung cancer screening has led to the discovery of
over 1 million pulmonary nodules each year. New
technology allows pulmonologists to perform percu-
taneous lung biopsies using electromagnetic
(EM) guided technology. In this retrospective analy-
sis, we demonstrate that EM percutaneous needle
biopsy is safe, feasible and provides an acceptable
diagnostic yield.
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tomography (CT) screening compared to conventional
radiology for the detection of lung cancer.1 With over
8 million Americans meeting the criteria for lung can-
cer screening,2 accurate and rapid diagnosis of suspi-
cious solitary pulmonary nodules (SPN) is needed.
There are over 10 million chest CT scans performed
each year in the United States in which an estimated
1.5 million nodules are discovered.3–5 This number is
expected to increase given the endorsement of low-
dose CT scans for lung cancer screening by the US Pre-
ventative Services Task Force (USPSTF).1,6 Successful
diagnosis of an early stage lung cancer gives an oppor-
tunity to cure patients of the disease; however, the
majority of nodules biopsied will be benign and thus
improved minimally invasive techniques are needed to
help reduce unnecessary surgery.7
The current common procedures used to diagnose
SPN are surgical biopsy, percutaneous lung biopsy and
bronchoscopy.8 Surgical biopsies have a high diagnos-
tic yield, but at the cost of undergoing a more invasive
and lengthy procedure under general anaesthesia and
a higher morbidity than either of the other two options.
Typically, interventional radiologists perform percuta-
neous lung biopsies under CT guidance, often perform-
ing multiple pleural punctures to make a diagnosis in
real time. Although diagnostic yield is higher than
bronchoscopy alone, this comes at the cost of higher
procedural complications. A large population-based
study of over 15 000 patients found a 16% pneumotho-
rax rate and a 1% risk of major haemorrhage in patients
undergoing a CT-guided lung biopsy.9 Although the
bronchoscopic yield for SPN historically remains low,
some advantages to bronchoscopy include a lower
complication rate10 as well as the ability to stage the
disease at the time of diagnosis with mediastinal and
hilar sampling using endobronchial ultrasound
(EBUS).11
A recent technological advancement, electromag-
netic (EM) guided percutaneous lung biopsy, has
become available. The system allows clinicians to
biopsy an SPN by performing a single percutaneous
pass through the visceral pleural under EM guidance
alone without the need for real-time CT or fluoroscopic
guidance. The procedure is performed under EM guid-
ance that is linked to a CT scan obtained just prior to
the procedure.
This platform provides proceduralists the novel
capability of performing an algorithmic approach to
the procedure to potentially optimize yield and
decrease procedural complications by performing
EBUS for lymph node staging first in the presence of
rapid on-site evaluation (ROSE) and if there is no evi-
dence of nodal involvement, under the same proce-
dural setting, attempt an EM-guided bronchoscopy.
The EM-guided bronchoscopy and EM percutaneous
lung biopsy can be performed using the same soft-
ware. If a diagnosis is unachievable with a broncho-
scopic approach, the proceduralist can pivot again to
perform an EM-guided percutaneous lung biopsy dur-
ing the same procedural setting. This procedure may
take place in a procedure suite or operating room,
and adds approximately 20 min to the total procedure
time.12
The goal of this study was to assess the safety, feasi-
bility and diagnostic yield of pulmonologists perform-
ing an EM-guided percutaneous lung biopsy.
METHODS
This was a multicentre, retrospective study on pulmo-
nologist performed EM percutaneous lung biopsies from
November 2013 through March 2017. Institutional
Review Board approval with waiver of consent was
obtained from each of the 10 individual institutions
(Institutional Review Board 00116317) prior to initiation
of data collection. All patients who received an EM per-
cutaneous lung biopsy were identified using CPT codes
(32405 and 10022) and were included in the data analy-
sis. All procedures were performed using the Veran
SPiNperc EM guidance system (Veran Medical, St Louis,
MO, USA). The outcomes for this study included safety,
feasibility and diagnostic yield of this procedure.
All patients were referred to pulmonology for a lung
lesion suspicious for cancer, and were scheduled to
undergo EM navigational bronchoscopy and EM-
guided percutaneous lung biopsy. All patients received
a chest CT scan on the day of the procedure with
0.5 mm intervals and 0.67–0.75 mm thickness, with
navigational tracking pads (vPAD2, Veran Medical) in
place which leads to the creation of a trackable virtual
airway map (Veran Medical). Pre-procedure, using the
software platform, the physician performing the proce-
dure identified and marked the target lesion and deter-
mined where on the chest wall the needle would be
placed in order to percutaneously access the lesion.
The software then provided the site of entry and trajec-
tory of the needle during real-time EM guidance for
the percutaneous approach. All patients were placed
under moderate or deep sedation for the bronchoscopy,
which was continued throughout the duration of the
procedure if EM-guided percutaneous needle biopsy
was performed. An EM tip tracked biopsy needle intro-
ducer was used under navigational guidance to identify
the previously determined entry site. Upon localization
of the nodule, an introducer needle was passed through
the visceral pleura and a 20-gauge Chiba needle used
for fine-needle aspiration followed by a 20-gauge coaxial
core biopsy instrument (SuperCore Argon Medical,
Frisco, TX, USA) was utilized through the introducer
needle to obtain tissue samples. Upon completion of the
lung biopsy, the introducer needle was removed and a
bandage was placed. The complete details of this proce-
dure have been previously described and are illustrated
in Figure 1.12 Upon completion of the procedure, all
patients were evaluated by chest X-ray or thoracic ultra-
sound for pneumothorax.
Data analysis
Demographic information, including age, sex, race,
smoking history and history of lung disease, was col-
lected. Characteristics of the biopsied nodule including
location, size, morphology, distance from the pleura
and Positron emission tomography scan avidity were
collected. The number of tissue samples, adverse
events and diagnostics were recorded when available.
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Additional adverse event data were collected, including
rates of pneumothorax, site of bleeding, haemoptysis,
infection and post-procedure admission. Diagnostic
yield data, including adequacy of sample, EM-guided
percutaneous lung biopsy and FNA yield, if another
procedure was performed and associated yield and
final diagnosis were obtained. A biopsy was deemed
diagnostic only if there was a definitive neoplastic diag-
nosis (adenocarcinoma, small cell carcinoma, etc.) or a
definitive benign diagnosis (fibrosis, granuloma, etc.)
with confirmed radiographic stability up to 1 ear. Cel-
lular atypia or lung parenchyma without a confirmed
pathologic diagnosis, with or without radiographic sta-
bility, was considered incomplete in the final analysis.
All patients with incomplete data were excluded from
the diagnostic analysis of the statistics.
A large proportion of participants were obtained
from a single centre. Because of this, we conducted a
secondary analysis comparing this site to the remaining
sites pertaining to diagnostic yield and adverse event
data. Continuous variables are described using means
with SD or range. Dichotomous variables are summa-
rized as simple proportions. Simple t-tests were used to
compare populations when necessary. Logistic regres-
sion was used to identify potential risk factors for both
adverse events and diagnostic yield. A P-value of <0.05
was considered statistically significant. All statistics
were performed using STATA 14.2 (StataCorp LLC, Col-
lege Station, TX, USA).
RESULTS
There were 129 patients who received EM-guided per-
cutaneous lung biopsies identified at 10 centres. A con-
sort diagram can be found in Figure 2. Of these
centres, seven were academic sites and three
community sites. The average age of participants was
65.6 years, and half were females. The baseline charac-
teristics are shown in Table 1.
The characteristics of the lesions sampled are shown
in Table 2. The majority of lesions were located in the
upper lobes. There was a mean of one pass of the
introducer needle into the target (range: 1–3) per-
formed per patient with the introducer needle. There
were two FNA (range: 0–7) and five core (range: 0–10)
biopsies taken.
Adverse event data are presented in Table 3. The
location of the nodule biopsied was not an indepen-
dent risk factor for an adverse event (OR: 0.87; 95% CI:
0.67, 1.13). Given these findings, it was excluded from
the multivariable analysis. There was no association
between the presence of an adverse event and size of
the lesion (OR: 0.97; 95% CI: 0.94, 1.01; for each 1 mm
increase in nodule size). There was a trend towards
increased risk of adverse events seen with increasing
distance from the pleura (OR: 1.02; 95% CI: 0.99, 1.05;
for each 1 mm increase in nodule size). The presence
Figure 1 Electromagnetic (EM) navigational trackpad placement and percutaneous lung biopsy planning programme. The panel on
the left shows the placement of the tracking pads needed prior to computed tomography (CT) scan to utilize the EM navigational soft-
ware. These pads can be shifted to the left or the right in order to clear access for the percutaneous lung biopsy. The panel on the right
shows the planning screen used prior to performing the transcutaneous needle biopsy. The programme will identify the nodule, which
can be optimized by the user, followed by placement of a virtual percutaneous needle. The placement of the needle aids the user in
locating the optimal site to perform the percutaneous needle biopsy.
Figure 2 Patient recruitment flow diagram.
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of emphysema on CT scan, history of COPD and num-
ber of pack-years smoking also did not lead to
increased odds of an adverse event. As the size of
lesion increased, there was a decreased risk of pneu-
mothorax (OR: 0.95; 95% CI: 0.90, 1.01; for each 1 mm
increase in nodule size). There was no association
between the number of pleural punctures with the
introducer needle and risk of pneumothorax. There
was also no association between the number of core
biopsies, or FNA, and the risk of an adverse event.
Ninety-five participants had complete data reporting
available for diagnostic yield, after excluding patients
with incomplete data as defined in the methods.
The overall diagnostic yield of EM-guided percutane-
ous lung biopsy was 73.7%. A detailed list of diagnoses
can be found in Table 4. There was no association
between diagnostic yield using EM-guided percutane-
ous needle biopsy and lesion size (OR: 1.03; 95% CI:
0.99, 1.08) which remained insignificant when analysed
as a categorical variable. There was also no association
in diagnostic yield and distance from the pleura (OR:
0.99; 95% CI: 0.96, 1.02), anatomical location (OR: 0.92;
95% CI: 0.69, 1.22), number of punctures (OR: 1.80;
95% CI: 0.43, 7.44), number of fine-needle aspirations
(OR: 1.06; 95% CI: 0.70, 1.59) or the number of core
biopsies obtained (OR: 0.78; 95% CI: 0.57, 1.08). When
the lesion was abutting the pleura, there was a diag-
nostic yield of 85% and a lower pneumothorax rate of
10%. Patients who developed a pneumothorax also had
an overall lower diagnostic rate of 63%. When EM-
guided bronchoscopic sampling was also performed
during the same procedural encounter, the overall
diagnostic yield increased to 81.1%.
Fifty-one percent of all procedures were conducted
at a single site. When comparing this site to the rest of
the locations, where 10 or less cases were performed
at each site, there was a higher yield and lower com-
plication rate, although these results did not reach sta-
tistical significance. The single site had an 18.1%
adverse event rate versus 27% at the remainder of the
sites (P = 0.23). The single site also had a 15.1% pneu-
mothorax rate versus 20.6% at the remaining sites
(P = 0.42). Of the patients who had a pneumothorax,
7.6% received chest tubes at the single site, while
17.5% received chest tubes at the remaining sites
(P = 0.09). There was also a diagnostic rate of 78.4% at
the single centre versus 68.1% at the remaining
sites (P = 0.26).
Table 2 Lung nodule characteristics
Characteristics All patients
Location (%)
Right upper lobe 37.21
Right middle lobe 10.85
Right lower lobe 7.75
Left upper lobe 31.78
Left lower lobe 7.75
Lingula 4.65
Size (mm), mean (range) 27.31 (9–140)
Distance from the pleura (mm), mean
(range)
13.20 (0–63)
Table 1 Baseline characteristics
Characteristic All patients
Age, mean (range) 65.52 (27–91)
Female sex (%) 50.40
BMI, mean (SD) 26.30 (5.97)
Race (%)
White 61.24
Black 18.60
Smoking history
Current (%) 31.78
Prior (%) 51.16
Never (%) 17.05
Pack-years, mean (SD) 28.0 (23.56)
History of COPD (%) 38.76
History of emphysema on CT (%) 55.04
CT, computed tomography.
Table 3 Adverse events
Adverse event
Percentage of
patients (n = 129)
Overall 29 (22.5%)
Pneumothorax 23 (17.8%)
Requiring chest tube
placement
16 (12.4%)
Minor bleeding 2 (1.6%)
COPD exacerbation 1 (0.78%)
Transient hypercapnia 2 (1.6%)
Transient hypoxaemia 1 (0.78%)
Table 4 Diagnoses obtained, electromagnetic
percutaneous diagnosis versus all diagnoses
Diagnosis
Percutaneous
diagnosis
(n = 70)
All
diagnoses
(n = 95)
Malignant
Adenocarcinoma 23 (31.9%) 32 (33.7%)
Squamous cell
carcinoma
13 (18.1%) 20 (21.1%)
Neuroendocrine 3 (4.2%) 3 (3.2%)
Sarcomatoid carcinoma 2 (2.8%) 2 (2.1%)
Hurthle cell 1 (1.4%) 1 (1.1%)
NSCLC, undifferentiated 1 (1.4%) 1 (1.1%)
Metastases 1 (1.4%) 4 (4.2%)
SCLC 0 1 (1.1%)
Benign
Fibrosis 6 (8.3%) 6 (6.3%)
Granuloma 6 (8.3%) 8 (8.4%)
COP 5 (6.9%) 5 (5.3%)
Inflammatory 5 (6.9%) 5 (5.3%)
Infection 3 (4.2%) 5 (5.3%)
Hamartoma 1 (1.4%) 2 (2.1%)
NSCLC, Non-Small Cell Lung Cancer; SCLC, Small Cell Lung
Cancer.
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DISCUSSION
Until the introduction of EM-guided percutaneous lung
biopsy, the routine options for percutaneous lung biop-
sies were performed with CT or ultrasound guidance.
CT guidance has been the gold standard for the mini-
mally invasive diagnosis of SPN with a high diagnostic
yield but also a high complication rate when compared
to bronchoscopy.11,13–15 Complication rates of 38.8% for
core biopsies and 24% for FNA from radiologists per-
forming CT-guided percutaneous lung biopsy were
reported in a recent meta-analysis.16 Another new
approach to diagnosing these lesions includes bron-
choscopic transparenchymal biopsies, in which pilot
studies have shown to have a diagnostic yield of 83%,
although with a higher pneumothorax rate (up to
33%).17,18 A combined procedural approach for the
diagnosis of pulmonary nodules by attempting a bron-
choscopic diagnosis first to limit complications, fol-
lowed by a percutaneous biopsy if the bronchoscopy is
non-diagnostic, may be effective in limiting overall
complications and increasing diagnostic yield. How-
ever, the feasibility to attempt a combined approach
has been limited as few centres have a CT scanner
within the bronchoscopy suite and lesions must abut
the pleura to allow for adequate visualization under
ultrasound guidance.19 In this study, we show that EM-
guided percutaneous lung biopsy was feasible with an
acceptable safety profile in the hands of pulmonolo-
gists, with diagnostic yields approaching CT-guided
biopsies.
We did not identify an association between the num-
ber of pleural punctures with the introducer needle
and risk of pneumothorax. This is likely due to the low
number of participants (n = 11) who received greater
than one pleural puncture. Of these 11, 3 (27%) suf-
fered a pneumothorax in comparison to the rest of the
participants in the study who only received one pleural
puncture, with a 17.8% pneumothorax rate. The diag-
nostic rate of patients who had a pneumothorax was
lower, at 63%. This is likely because the pneumothorax
would lead to a shift in the nodule, which would likely
not be accurately tracked by the software. Similar drops
in diagnostic yield are reported in the CT-guided
literature.
Until the implementation of EM-guided percutane-
ous lung biopsy, the only options for percutaneous
lung biopsies were CT-guided and ultrasound-guided.
CT-guided lung biopsy has been the standard for mini-
mally invasive diagnosis of SPN, and has been shown
to have a higher diagnostic yield than bronchoscopy
alone.11,13–15 We have shown that EM-guided percuta-
neous needle biopsy is not only safe, but also has a
diagnostic yield that may approach CT-guided percuta-
neous needle biopsies. Combining the use of EM-
guided percutaneous lung biopsy with EM navigational
bronchoscopy increased our diagnostic yield to 81.1%.
Conceptually, this not only provides overall improved
diagnostic yield over bronchoscopy alone, but also
leads to a decrease in overall pneumothorax rates by
limiting the percutaneous approach to only those cases
where ROSE is non-diagnostic for the bronchoscopic
phase of the procedure. Further increases in yield and
decreases in complications may also be seen with inte-
gration of EBUS with ROSE as the initial procedure but
prospective validation is warranted.
Practitioner training is another important aspect of
all procedures. With proper training on how to use the
navigational software and equipment, coupled with
expert teaching, competency in EM-guided percutane-
ous lung biopsy significantly increases.20 This is dem-
onstrated by our analysis showing that experts, who
performed at a single centre with the highest volume of
EM-guided percutaneous lung biopsies, had a higher
diagnostic rate and lower complication rate than their
counterparts. By undergoing appropriate training, the
provider is able to better manipulate the angle of entry
into the lesion, interpret the respiratory variation and
limit their technique to a single pleural puncture.
There are limitations to this study. The study was ret-
rospective, limiting us to data available by chart review.
In addition, patients were identified by CPT codes
showing that a patient received an EM percutaneous
lung biopsy; this referral bias was not controlled for.
Although this was a multicentre retrospective chart
review, many of the physicians had limited experience
with EM-guided percutaneous lung biopsy. All but one
site performed under 10 procedures, and 51.2% of the
participants included were seen at a single large aca-
demic centre, which also limits the generalizability.
This highest volume single centre had a lower pneu-
mothorax rate, 15% (7.6% chest tube rate), as well as a
higher diagnostic yield (78.4%), although not statisti-
cally different from the pooled diagnostic yield and
pneumothorax rate from the remaining centres. This
leads us to believe that as centres perform more EM-
guided percutaneous lung biopsies, there will be
increased safety and diagnostic yield. In addition, 32%
of the lesions diagnosed were confirmed benign thus
reducing potential surgical complications by limiting
benign resection rates. Lastly, we only received com-
plete diagnostic data for 95 (74%) subjects. Given the
retrospective nature of this study, it was difficult to
obtain follow-up data on patients, and we elected to
include only complete data in order to report the cur-
rent true results.
Although the pneumothorax rates were lower than
many reported studies on CT-guided percutaneous
lung biopsies, there was an overall chest tube rate of
12.4%, which is higher than some reported studies in
patients undergoing CT-guided biopsy. Our lower
pneumothorax rate, in comparison to CT-guided biop-
sies, may be a function of imaging modality used to
diagnose pneumothoraces. CT-guided biopsies verify
the presence or absence of a pneumothorax using the
CT scanner which is highly sensitive to diagnosing a
pneumothorax, where the patients in this series were
diagnosed using a combination of chest X-rays and
thoracic ultrasound. Despite this, when adjusting for
risk factors related to pneumothorax, we found that the
highest volume single centre had a lower pneumotho-
rax rate, 15% (7.6% chest tube rate), as compared to
the entire study cohort. This leads us to believe that as
centres perform more EM-guided percutaneous lung
biopsies, there may be an overall decrease in pneumo-
thorax rates. The authors also hypothesize that the cli-
nicians in this study may also have had a lower
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threshold to place chest tubes in the setting of a newer
technique in conjunction with the use of minimally
invasive small-bore chest tubes (8Fr or 14Fr) in all
cases reported. No patients in the study suffered from a
prolonged air leak.
In this study, we show that an EM-guided percutane-
ous lung biopsy approach yields a high diagnostic rate
with minimal safety concerns and the added benefit of
using a combined bronchoscopic and percutaneous
staged approach to pulmonary nodule diagnostics in a
single procedural setting. A prospective multicentre
trial to validate these findings is currently underway
(NCT03338049).21
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